Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

36 citing papers in PubMed, 49 citations in OpenAlex.

1. Updated oncolytic viruses for the treatment of bladder cancer: a systematic review.Iranian journal of microbiology · 2026
   Review
2. Dynamic 3D microfluidic platform for exploring combined targeted therapy, chemotherapy, and virotherapy delivery in ovarian cancer.Drug delivery and translational research · 2026
   Article
3. An ex vivo permissivity assay to assess replication of the oncolytic virus VSV-GP in patient-derived tumor samples.Oncogene · 2026
   Article
4. Oncolytic myxoma virus and engineering strategies for advanced cancer immunotherapy.iScience · 2026
   Review
5. Recent advances in oncolytic virotherapy: insights from clinical trials and combination treatment strategies.Virology journal · 2026
   Review
6. Current use of pre-clinical models for evaluation of human adenovirus-based cancer therapeutics.Molecular therapy. Oncology · 2026
   Review
7. Oncolytic viruses: advanced strategies in cancer therapy.Signal transduction and targeted therapy · 2026
   Review
8. Harnessing live vectors for cancer vaccines: Advancing therapeutic immunotherapy.Human vaccines & immunotherapeutics · 2025
   Review
9. Recent advances in oncolytic virus combined immunotherapy in tumor treatment.Genes & diseases · 2025
   Review
10. CARG-2020 targets IL-12, IL-17, and PD-L1 pathways to effectively treat melanoma and breast cancer.Scientific reports · 2025
    Article
11. The evolving landscape of oncolytic virus immunotherapy: combinatorial strategies and novel engineering approaches.Medical oncology (Northwood, London, England) · 2025
    Review
12. Oncolytic Vaccinia Virus Armed with GM-CSF and IL-7 Enhances Antitumor Immunity in Pancreatic Cancer.Biomedicines · 2025
    Article
13. Opportunities, challenges, and future perspectives of oncolytic virus therapy for malignant melanoma.Frontiers in immunology · 2025
    Review
14. Oncolytic adenovirus H101 enhances the anti-tumor effects of PD-1 blockade via CD47 downregulation in tumor cells.Oncology research · 2025
    Article
15. Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides.Human vaccines & immunotherapeutics · 2024
    Review
16. Virus nanotechnology for intratumoural immunotherapy.Nature reviews bioengineering · 2024
    Article
17. Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy.Nature protocols · 2024
    Review
18. Systemic Therapy for Non-Melanoma Skin Cancers: Latest Advances.Current oncology reports · 2024
    Review
19. miRNA-Mediated Mechanisms in the Generation of Effective and Safe Oncolytic Viruses.Pharmaceutics · 2024
    Review
20. The Complex Tumor Microenvironment in Ovarian Cancer: Therapeutic Challenges and Opportunities.Current oncology (Toronto, Ont.) · 2024
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as